Actuate Therapeutics, Inc. (ACTU) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Actuate Therapeutics reported revenue of $0. Net income was -$22.2M, or -$1.06 per diluted share. Operating activities generated -$19.2M of cash. At fiscal year end, Actuate Therapeutics held $14.0M in total assets against $6.1M in total liabilities, including $13.2M of cash and equivalents.
Open the full interactive Actuate Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Actuate Therapeutics Key Stats
| Share Price | $0.47 |
|---|---|
| Market Cap | $11.1M |
| 52-Week Range | $0.47 – $8.09 |
| Shares Outstanding | 23.9 million (basic, 2026 Q2) |
Actuate Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$25.2M | -$22.5M |
| Pre-Tax Income | -$27.3M | -$22.2M |
| Income Tax | $800 | $800 |
| Net Income | -$27.3M | -$22.2M |
| Diluted EPS | -$3.26 | -$1.06 |
Actuate Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$5.4M | -$4.6M | -$5.6M | -$4.9M |
| Diluted EPS | -$0.25 | -$0.22 | -$0.24 | -$0.20 |
Actuate Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $8.6M | $13.2M |
| Current Assets | $9.2M | $13.6M |
| Total Assets | $9.3M | $14.0M |
| Current Liabilities | $8.8M | $5.7M |
| Total Liabilities | $9.2M | $6.1M |
| Shareholders' Equity | $104,186 | $7.9M |
Actuate Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$21.8M | -$19.2M |
| Cash From Financing | $27.5M | $23.7M |
Figures from Actuate Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Actuate Therapeutics financials page for every line item.
Actuate Therapeutics Company Profile
| Ticker | ACTU |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Fort Worth, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001652935 |
Frequently Asked Questions
What was Actuate Therapeutics' revenue in fiscal 2025?
Actuate Therapeutics (ACTU) reported revenue of $0 for fiscal 2025.
What was Actuate Therapeutics' net income in fiscal 2025?
Actuate Therapeutics reported net income of -$22.2M for fiscal 2025.
What was Actuate Therapeutics' earnings per share (EPS) in fiscal 2025?
Actuate Therapeutics' diluted EPS was -$1.06 for fiscal 2025 (adjusted for any later stock splits).
What was Actuate Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Actuate Therapeutics reported revenue of $0.
How many shares of Actuate Therapeutics are outstanding?
Actuate Therapeutics reported a weighted average of 23.9 million basic shares outstanding in 2026 Q2.
What is Actuate Therapeutics' market cap?
Based on its latest closing price, Actuate Therapeutics (ACTU) has a market capitalization of about $11.1M.
When does Actuate Therapeutics' fiscal year end?
Actuate Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Actuate Therapeutics headquartered?
Actuate Therapeutics lists its business address in Fort Worth, Texas in its SEC filings.